The latest update is out from Xeris Pharmaceuticals (XERS).
Paul R. Edick is stepping down as CEO and Chairman of a company to become a Senior Advisor until February 2026. John Shannon, the current President and COO, will take over as CEO and join the Board as a Class III director, while Marla S. Persky will become the Chairperson of the Board. Shannon’s extensive pharmaceutical experience and understanding of the company’s business strategy are key to his qualifications. Edick’s transition includes a severance package and continued vesting in RSUs, while Shannon’s new agreement includes a substantial salary, incentives, and stock-related benefits, with provisions for termination scenarios.
For an in-depth examination of XERS stock, go to TipRanks’ Stock Analysis page.
